Research on pricing methods of multi-indication drugs from the perspective of economics

YANG Fenghong; JIAN Jinyang; LIU Dongxu; CHU Shuzhen

doi:10.6039/j.issn.1001-0408.2023.17.15

您当前的位置：

首页 >

文章列表页 >

Research on pricing methods of multi-indication drugs from the perspective of economics

更新时间：2023-09-14

- Research on pricing methods of multi-indication drugs from the perspective of economics
- ZHONGGUO YAOFANG Vol. 34, Issue 17, Pages: 2134-2138(2023)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.17.15
  CLC： R956
- Published：15 September 2023，
  
  Received：29 March 2023，
  
  Revised：17 August 2023，
扫描看全文
阳丰鸿,简金洋,刘东旭等.经济学视角下我国多适应证药物定价方式探究 ^Δ[J].中国药房,2023,34(17):2134-2138.

YANG Fenghong,JIAN Jinyang,LIU Dongxu,et al.Research on pricing methods of multi-indication drugs from the perspective of economics[J].ZHONGGUO YAOFANG,2023,34(17):2134-2138.
阳丰鸿,简金洋,刘东旭等.经济学视角下我国多适应证药物定价方式探究 ^Δ[J].中国药房,2023,34(17):2134-2138. DOI： 10.6039/j.issn.1001-0408.2023.17.15.

YANG Fenghong,JIAN Jinyang,LIU Dongxu,et al.Research on pricing methods of multi-indication drugs from the perspective of economics[J].ZHONGGUO YAOFANG,2023,34(17):2134-2138. DOI： 10.6039/j.issn.1001-0408.2023.17.15.

摘要

目的

从经济学角度探讨适合我国的多适应证药物定价方式。

方法

通过梳理多适应证药物近几年在我国医保谈判准入的情况和定价方式，从品牌定价、加权平均标价、风险分担协议下的单一标价3种方式探讨典型国家（瑞典、德国、英国、意大利等）对多适应证药物的价值测算、准入与管理经验，并以社会福利相关理论为支撑，探究单一标价、适应证定价2种多适应证药物定价方式的优劣及使用条件，从而提出适合我国多适应证药物的定价方式。结果与

结论

多适应证药物采用单一标价模式定价在现阶段存在一定的弊端，应适当以协议定价的方式进行补充完善。我国可在借鉴国际经验的基础上，探索合理的药品适应证管理模式，采用以协议定价为主、多种定价方式并存的定价模式，并推进药物经济学评价发展和用药信息收集机制的完善。

Abstract

OBJECTIVE

METHODS

By sorting out the situation and pricing methods of multi-indication drugs in China’s health insurance negotiation in recent years， the experience of typical countries （Sweden， Germany， Britain， Italy， etc.） in the value measurement， access and management of multi-indication drugs were explored with 3 methods， namely， branded pricing， weighted average bidding pricing， and single bidding pricing under the risk sharing agreement. The advantages and disadvantages of the 2 types of multi-indication drug pricing methods， such as single bidding pricing and indication-based pricing， and conditions of use were explored， so as to put forward a pricing method suitable for multi-indication drugs in China.

RESULTS

CONCLUSIONS

The pricing of multi-indication drugs by single bidding pricing mode has certain disadvantages at this stage， and should be supplemented and improved by agreement pricing. Based on international experience， China can explore a reasonable management mode of drug indications， adopt a pricing mode with agreement pricing as the main mode and multiple pricing modes as the coexisting mode， and promote the development of pharmacoeconomic evaluation and the improvement of drug use information collection mechanism.

＆

To explore the pricing methods of multi-indication drugs suitable for China from the economic perspective.

关键词

多适应证药物协议定价价值定价医保准入医保药品支付标准

Keywords

negotiated pricingvalue pricingmedicare insurance accesspayment standards for medicare insurance drug

references

OECD. Addressing challenges in access to oncology medicines[EB/OL].（2020-06-05）[2023-03-05].https：//www.oecd.org/health/health-systems/addressing-challenges- in-access-to-oncology-medicines.htmhttps://www.oecd.org/health/health-systems/addressing-challenges-in-access-to-oncology-medicines.htm.

MESTRE-FERRANDIZ J，DELLAMANO R，PISTOLLATO M，et al. Multi-indication pricing：pros，cons and applicability to the UK[EB/OL].[2023-03-05].https：//ideas.repec.org/p/ohe/sembri/001653.htmlhttps://ideas.repec.org/p/ohe/sembri/001653.html.

PERSSON U，NORLIN J M. Multi-indication and combination pricing and reimbursement of pharmaceuticals：opportunities for improved health care through faster uptake of new innovations[J]. Appl Health Econ Health Policy，2018，16（2）：157-165.

CHANDRA A，GARTHWAITE C. The economics of indication-based drug pricing[J]. N Engl J Med，2017，377（2）：103-106.

NERI M，TOWSE A，GARAU M. Multi-indication pricing（MIP）：practical solutions and steps to move forward[EB/OL].[2023-03-05]. https：//ideas.repec.org/p/ohe/briefg/002084.htmlhttps://ideas.repec.org/p/ohe/briefg/002084.html.

MOSSMANN W，SCHERRER F. PCP1：comparison of the German mixed price model and indication-specific pricing for multi-indication products in oncology[J]. Value Heath，2018，21：S82.

PEARSON S D，DREITLEIN W B，HENSHALL C，et al. Indication-specific pricing of pharmaceuticals in the US healthcare system[J]. J Comp Eff Res，2017，6（5）：397-404.

LAUENROTH V D，STARGARDT T. Pharmaceutical pricing in Germany：how is value determined within the scope of AMNOG?[J]. Value Health，2017，20（7）：927-935.

Department of Health and Social Care. The 2019 voluntary scheme for branded medicines pricing and access[EB/OL].（2018-12-06）[2023-03-05]. https：//assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-brandedme- dicines-pricing-and-access-chapters-and-glossary.pdfhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-brandedme-dicines-pricing-and-access-chapters-and-glossary.pdf.

JOMMI C，MINGHETTI P. Pharmaceutical pricing policies in Italy[EB/OL]. （2014-11-28）[2023-03-05]. https：//doi.org/10.1007/978-3-319-12169-7_8https://doi.org/10.1007/978-3-319-12169-7_8.

ZOZAYA N，MESTRE J，ALCALÁ B，et al. Medicines with multiple indications：a new multi-year multi-indication pricing model[EB/OL].（2020-06-30）[2023-03-05]. http：//weber.org.es/wp-content/uploads/2020/04/Informe-VOICE-FINAL-Abril-2020-1.pdfhttp://weber.org.es/wp-content/uploads/2020/04/Informe-VOICE-FINAL-Abril-2020-1.pdf.

Department of Health and Social Care. Pharmaceutical price regulation scheme 2014[EB/OL].（2018-12-03）[2023-03-05]. https：//www.gov.uk/government/publications/pharma-ceutical-price-regulation-scheme-2014https://www.gov.uk/government/publications/pharma-ceutical-price-regulation-scheme-2014.

NAVARRIA A，DRAGO V，GOZZO L，et al. Do the current performance-based schemes in Italy really work? “Success fee”：a novel measure for cost-containment of drug expenditure[J]. Value Health，2015，18（1）：131-136.

LEELE B. Patient access schemes：a look behind the scenes[EB/OL].（2015-12-08）[2023-03-05]. https：//pharmaphorum.com/views-and-analysis/patient-accessschemes- a-lookbehind-the-scenes/https://pharmaphorum.com/views-and-analysis/patient-accessschemes-a-lookbehind-the-scenes/.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰